J&J Ordered to Pay $327 Million Over Deceptive-Marketing Claims

A Johnson & Johnson unit was ordered by a South Carolina judge to pay more than $327 million in penalties for deceptively marketing the antipsychotic drug Risperdal as safer and better than competing medicines.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.